SEOM clinical guidelines on cardiovascular toxicity (2018)
Por:
Virizuela J, Garcia A, de las Penas R, Santaballa A, Andres R, Beato C, de la Cruz S, Gavila J, Gonzalez-Santiago S, Fernandez T
Publicada:
1 ene 2019
Resumen:
One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients.
Filiaciones:
Virizuela J:
Complejo Hosp Reg Virgen Macarena, Serv Oncol Med, Av Doctor Fedriani 3, Seville 41009, Spain
Garcia A:
Complejo Asistencial Univ Salamanca CAUSA, Inst Invest Biomed Salamanca IBSAL, Serv Cardiol, Ciber CV, Salamanca, Spain
de las Penas R:
Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana, Spain
Santaballa A:
Hosp Univ & Politecn La Fe, Serv Oncol Med, Valencia, Spain
Andres R:
Hosp Clin Univ Lozano Blesa, Serv Oncol Med, Zaragoza, Spain
Beato C:
Complejo Hosp Reg Virgen Macarena, Serv Oncol Med, Seville, Spain
de la Cruz S:
Complejo Hosp Navarra, Serv Oncol Med, Pamplona, Spain
Gavila J:
Fdn Inst Valenciano Oncol IVO, Serv Oncol Med, Valencia, Spain
Gonzalez-Santiago S:
Complejo Hosp Univ Caceres, Serv Oncol Med, Caceres, Spain
Fernandez T:
Hosp Univ La Paz, IdiPAZ, CiberCV, Serv Cardiol, Madrid, Spain
|